Structure-activity relationships and drug allergy

Current Clinical Pharmacology

Volumn 7, Issue 1, 2012, Pages 15-27

  Hasdenteufel, Frédéric ^a   Luyasu, Samuel ^b   Hougardy, Nicolas ^c   Fisher, Malcolm ^d   Boisbrun, Michel ^e   Mertes, Paul Michel ^f   Kanny, Gisèle ^a  

^a Clinical Immunology and Allergology ^*  (France)

^b UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^c Department of Clinical Biology   (Belgium)

^d UNIVERSITY OF SYDNEY   (Australia)

^e NANCY UNIVERSITÉ   (France)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Contact dermatitis; Drug allergy; Drug hypersensitivity; SAR; Structure activity relationships

Indexed keywords

AMOXICILLIN; ATRACURIUM BESILATE; BETAMETHASONE; BUDESONIDE; CAPTOPRIL; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN; CLOBETASONE BUTYRATE; DALFOPRISTIN; EPITOPE; HYDROCORTISONE BUTYRATE; MORPHINE; OXACILLIN; PANCURONIUM BROMIDE; PENICILLIN G; PHOLCODINE; PREDNICARBATE; PRISTINAMYCIN; QUINUPRISTIN; SAQUINAVIR; SULFANILAMIDE; SUXAMETHONIUM; TRIAMCINOLONE ACETONIDE; TRIMETHOPRIM; UNINDEXED DRUG; VIRGINIAMYCIN;

ANAPHYLACTIC SHOCK; BINDING SITE; CONTACT DERMATITIS; CONTRAST ENHANCEMENT; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SENSITIZATION; DRUG TOLERABILITY; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SKIN TEST; STRUCTURE ACTIVITY RELATION;

ANIMALS; CROSS REACTIONS; DERMATITIS, CONTACT; DRUG DESIGN; DRUG HYPERSENSITIVITY; HUMANS; IMMUNOGLOBULIN E; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 84857132819     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488412799218815     Document Type: Review

References (118)

1. Wermuth CG, Ganellin CR, Lindberg P, Mitscher LA. Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998). Pure Appl Chem 1998; 70: 1129-43.
2. Marshall GR, Cramer RD III. Three dimensional structure-activity relationships. Trends Pharmacol Sci 1988; 285-9.
3. Kubinyi H. 3D-QSAR in drug design: theory, methods and applications. Leiden: Kluwer/Escom 1993.
4. Green S, Marshall GR. 3D-QSAR: a current perspective. Trends Pharmacol Sci 1995; 16: 285-91.
5. Tong W, Lowis DR, Perkins R, et al. Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor. J Chem Inf Comput Sci 1998; 38: 669-77.
6. Cho SJ, Zheng W, Tropsha A. Focus-2D: a new approach to the design of targeted combinatorial chemical libraries. Pac Symp Biocomput 1998; 305-16.
7. Gao H, Bajorath J. Comparison of binary and 2D QSAR analyses using inhibitors of human carbonic anhydrase II as a test case. J Mol Diversity 1999; 4:115-30.
8. Gao H, Williams C, Labute P, Bajorath J. Binary quantitative structure-activity relationships (QSAR) analysis of estrogen receptor ligands. J Chem Inf Comput Sci 1999; 39: 164-8.
9. Crum-Brown A, Fraser TR. On the connection between chemical constitution and physiological action. Trans R Soc Edinburgh 1868; 25: 151-203.
10. Richet C. CR Séances Soc Biol 1893; 9: 775.
11. Meyer H. Zur Theorie der Alkoholnarkose. Erste Mitteilung, welche Eigenschaft der Anesthetica bedingt ihre narkotische Wirkung. Arch Exp Pathol Pharmakol 1899; 42: 109.
12. Overton E. Studien über die Narkose. Jena: Gustav Fischer Verlag 1901.
13. Hammett LP. The effect of structure on the reaction of organic compounds. Benzene derivatives. J Am Chem Soc 1937; 59: 96.
14. Taft RW. Polar and steric substituent constants for aliphatic and obenzoate groups from rates of esterification and hydrolysis of esters. J Am Chem Soc 1952; 74: 3120-8.
15. Hansch C, Maloney PP, Fujita T, Muir RM. Correlation of biological activity of phenoxyacetic acids with hammett substituent constants and partition coefficients. Nature 1962; 194: 178-80.
16. Fujita T, Iwasa J, Hansch C. A new substituent constant, derived from partition coefficients. J Am Chem Soc 1964; 86: 5175-80.
17. Hansch C, Fujita T. Rho sigma pi analysis: a method for the correlation of biological activity and chemical structure. J Am Chem Soc 1964; 86: 1616-26.
18. Martin YC. Quantitative drug design. New York: Marcel Dekker 1978.
19. Free SM, Wilson J. A mathematical contribution to structure-activity studies. J Med Chem 1964; 7: 395-9.
20. th ed. New-York: John Wiley & Sons Inc. 2003; 1: pp. 4.
21. Wiener H. Structural determination of paraffin boiling point. J Am Chem Soc 1947; 69: 17-20.
22. Hosoya H. Topological index. A newly proposed quantity characterizing topological nature of structural isomers of saturated hydrocarbons. Bull Chem Soc Jpn 1971; 44: 2332-9.
23. Randi M. On characterization of molecular branching. J Am Chem Soc 1975; 97: 6609-15.
24. Balaban AT. Highly discriminating distance-based topological index. Chem Phys Lett 1982; 89: 399-404.
25. Simon Z. Specific interactions. Intermolecular forces, steric requirements, and molecular size. Angew Chem Int Ed Eng 1974; 13: 719-27.
26. Kier LB, Hall LH. Molecular connectivity in chemistry and drug research. New-York: Academic Press 1976.
27. Hall LH, Kier LB. Structure-activity studies using valence molecular connectivity. J Pharm Sci 1977; 66: 642-4.
28. Kier LB, Hall LH. Molecular connectivity in structure-activity analysis. Letchworth: Research Studies Press 1986.
29. Van de Waterbeemd H, Carter RE, Grassy G, et al. Glossary of terms used in computational drug design (IUPAC recommendations 1997). Pure Appl Chem 1997; 69: 1137-52.
30. Moreira Lima L, Barreiro EJ. Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem 2005; 12: 23-49.
31. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977; 196: 441-4.
32. Cushman DW, Ondetti MA. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 1991; 17: 589-92.
33. Patlak M. From viper's venom to drug design: treating hypertension. FASEB J 2004; 18: 421.
34. Ferreira SH. A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol 1965; 24: 163-9.
35. Bakhle YS. Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. Nature 1968; 220: 919-21.
36. Byers LD, Wolfenden R. Binding of the biproduct analog benzylsuccinic acid by carboxypeptidase A. Biochemistry 1973; 12: 2070-8.
37. Navia MA, Fitzgerald PM, McKeever BM, et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989; 337; 615-20.
38. Wlodawer A, Miller M, Jaskolski M, et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 1989; 245: 616-21.
39. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990; 248: 358-61.
40. Vella S. HIV therapy advances. Update on a proteinase inhibitor. AIDS 1994; 8: S25-9.
41. Brik A, Wong CH. HIV-1 protease: mechanism and drug discovery. Org Biomol Chem 2003; 1: 5-14.
42. Goodwin BF, Roberts DW. Structure-activity relationships in allergic contact dermatitis. Food Chem Toxicol 1986; 24: 795-8.
43. Lepoittevin JP. Development of structure-activity relationships (SARs) in allergic contact dermatitis. Cell Biol Toxicol 1999; 15: 47-55.
44. Karlberg AT, Bergström MA, Börje A, Luthman K, Nilsson JLG. Allergic contact dermatitis - formation, structural requirements, and reactivity of skin sensitizers. Chem Res Toxicol 2008; 21: 53-69.
45. th Amendment to the European Cosmetics Directive"). Off J Eur Union L 2003; 66: 26-35.
46. Kimber I, Hilton J, Dearman RJ, et al. An international evaluation of the murine local lymph node assay and comparison of modified procedures. Toxicology 1995; 103: 63-73.
47. Basketter DA, Gerberick GF, Kimber I. Measurement of allergenic potency using the local lymph node assay. Trends Pharmacol Sci 2001; 22: 264-5.
48. Landsteiner K, Jacobs JL. Studies on the sensitization of animals with simple chemical compounds III. J Exp Med 1936; 64: 625-39.
49. Dupuis G, Benezra C. Allergic contact dermatitis to simple chemicals. A molecular approach. Marcel Dekker: New York 1982.
50. Roberts DW, Williams DL. The derivation of quantitative correlations between skin sensitisation and physicochemical parameters for alkylating agents, and their application to experimental data for sultones. J Theor Biol 1982; 99: 807-25.
51. Magee PS, Hostynek JJ, Maibach MI. A classification model for allergic contact dermatitis. Quant Struct Act Relat 1994; 13: 22-33.
52. Estrada E, Patlewicz G, Chamberlain M, Basketter D, Larbey S. Computer-aided knowledge generation for understanding skin sensitization mechanisms: the TOPS-mode approach. Chem Res Toxicol 2003; 16: 1226-35.
53. Estrada E, Patlewicz G, Gutierrez Y. From knowledge generation to knowledge archive. A general stratedy using TOPS-MODE with DEREK to formulate new alerts for skin sensitization. J Chem Inf Comput Sci 2004; 44: 688-98.
54. Li Y, Tseng YJ, Pan D, Liu J, Kern PS, Gerberick GF, Hopfinger AJ. 4D-fingerprint categorical QSAR models for skin sensitization based on the classification of local lymph node assay measures. Chem Res Toxicol 2007; 20: 114-28.
55. Barratt MD, Basketter DA, Chamberlain M, Admans GD, Langowski JJ. An expert system rulebase for identifying contact allergens. Toxic in Vitro 1994; 8: 1053-60.
56. Barratt MD, Basketter DA, Chamberlain M, Payne MP, Admans GD, Langowski JJ. Development of an expert system rulebase for identifying contact allergens. Toxic in Vitro 1994; 8: 837-9.
57. Coopman S, Degreef H, Dooms-Goossens A. Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids. Br J Dermatol 1989; 121: 27-34.
58. Lepoittevin JP, Drieghe J, Dooms-Goossens A. Studies in patients with corticosteroid contact allergy. Understanding cross-reactivity among different steroids. Arch Dermatol 1995; 131: 31-7.
59. Naisbitt DJ. Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests. Toxicology 2004; 194: 179-96.
60. Isaksson M, Bruze M, Goossens A, Lepoittevin JP. Patch-testing with serial dilutions of tixocortol pivalate and potential cross-reactive substances. Acta Dermato-Venereol 2000; 80: 33-8.
61. Naisbitt DJ, Gordon SF, Pirmohamed M, et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependant haptenation and T-cell proliferation in vivo. Br J Pharmacol 2001; 133: 295-305.
62. Barbaud A, Trechot P, Weber-Muller F, Ulrich G, Commun N, Schmutz JL. Drug skin tests in cutaneous adverse drug reactions to pristinamycin: 29 cases with a study of cross-reactions between synergistins. Contact Dermatitis 2004; 50: 22-6.
63. Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States, an investigation into its epidemiology. Arch Intern Med 2001; 161: 15-21.
64. Renaudin JMC, Kanny G, Codreanu F, Beaudouin E, Moneret-Vautrin DA. Severe drug-induced anaphylaxis: survey of case reports by allergy vigilance network. J Allergy Clin Immunol 2007; 119: S36.
65. Levine BB. Immunologic mechanisms of penicillin allergy. A haptenic model system for the study of allergic diseases in man. N Engl J Med 1966; 275: 1115-25.
66. Torres MJ, Blanca M, Fernandez J, et al. ENDA and the EAACI Interest Group on Drug Hypersensitivity. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 2003; 58: 961-72.
67. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology and the Joint Council of Allergy, Asthma and Immunology. Executive summary of disease management of drug hypersensitivity: A practice parameter. Ann Allergy Asthma Immunol 1999; 83: 665-700.
68. Baldo BA, Pham NH. Structure-activity studies on drug-induced anaphylactic reactions. Chem Res Toxicol 1994; 7: 703-21.
69. Baldo BA. Diagnosis of allergy to penicillins and cephalosporins. Structural and immunochemical considerations. Allergy Clin Immunol Int 2000; 12: 206-12.
70. Blanca M, Cornejo-Garcia JA, Torres MJ, Mayorga C. Specificities of B cell reactions to drugs. The penicillin model. Toxicology 2005; 209: 181-4.
71. Novalbos A, Sastre J, Cuesta J, et al. Lack of allergic cross-reactivity to cephalosporins among patients allergic to penicillins. Clin Exp Allergy 2001; 31: 438-43.
72. Poston SA, Jennings HR, Poe KL. Cefazolin tolerance does not predict ceftriaxone hypersensitivity: unique side chain precipitate anaphylaxis. Pharmacotherapy 2004; 24: 668-72.
73. DePestel DD, Benninger MS, Danziger L, et al. Cephalosporin use in treatment of patients with penicillin allergies. J Am Pharm Assoc 2008; 48: 530-40.
74. Hasdenteufel F, Luyasu S, Renaudin JM, Trechot P, Kanny G. Anaphylactic shock associated with cefuroxime axetil: structure-activity relationships. Ann Pharmacother 2007; 41: 1069-72.
75. Pichichero ME. A review of evidence supporting the American Academy of Pediatrics Recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005; 115: 1048-57.
76. Romano A, Viola M, Guéant-Rodriguez RM, Valluzzi RL, Guéant JL. Selective immediate hypersensitivity to cefodizime. Allergy 2005; 60: 1545-6.
77. Marcy SM, Klein JO. The isoxazolyl penicillins: oxacillin, cloxacillin and dicloxacillin. Med Clin North Am 1970; 54: 1127-43.
78. Neu HC. -lactam antibiotics: structural relationships affecting in vitro activity and pharmacologic properties. Rev Infect Dis 1986; 8: S237-59.
79. nd ed. Oxford: Oxford University Press, 2001.
80. Harle DG, Baldo BA. Identification of penicillin allergenic determinants that bind IgE antibodies in the sera of subjects with penicillin allergy. Mol Immunol 1990; 27: 1063-71.
81. Baldo BA, Pham NH, Weiner J. Detection and side-chain specificity of IgE antibodies to flucloxacillin in allergic subject. J Mol Recognit 1995; 8: 171-7.
82. Zhao Z, Baldo BA, Rimmer J. -lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin. Clin Exp Allergy 2002; 32: 1644-50.
83. Pham NH, Baldo BA. -lactam drug allergens: fine structural recognition patterns of cephalosporin-reactive IgE antibodies. J Mol Recognit 1996; 9: 287-96.
84. Sanchez-Sancho F, Perez-Inestrosa E, Suau R, et al. Synthesis, characterization and immunochemical evaluation of cephalosporin antigenic determinants. J Mol Recognit 2003; 16: 148-56.
85. Kim SH, Choi JH, Park HS. Heterogeneity of the IgE response to allergenic determinants of cefaclor in serum samples from patients with cefaclor-induced anaphylaxis. Ann Allergy Asthma Immunol 2005; 94: 700-4.
86. Antunez C, Blanca-Lopez N, Torres MJ, et al. Immediate allergic reactions to cephalosporins: evaluation of cross-reactivity with a panel of penicillins and cephalosporins. J Allergy Clin Immunol 2006; 117: 404-10.
87. Harle DG, Baldo BA, Well JV. Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole. Mol Immunol 1988; 25: 1347-54.
88. Verdel BM, Souverein PC, Egberts AC, Leufkens HG. Difference in risks of allergic reaction to sulfonamide drugs based on chemical structure. Ann Pharmacother 2006; 40: 1040-6.
89. Smal MA, Baldo BA, Harle DG. Drugs as allergens: the molecular basis of IgE binding to trimethoprim. Allergy 1988; 43: 184-91.
90. Mertes PM, Aimone-Gastin I, Guéant-Rodriguez RM, et al. Hypersensitivity reactions to neuromuscular blocking agents. Curr Pharm Des 2008; 14: 2809-25.
91. Baldo BA, Fisher MM. Substituted ammonium ions as allergenic determinants in drug allergy. Nature 1983; 306: 262-4.
92. Baldo BA, Fisher MM. Anaphylaxis to muscle relaxant drugs: cross-reactivity and molecular basis of binding of IgE antibodies detected by radioimmunoassay. Mol Immunol 1983; 20: 1393-400.
93. Baldo BA, Fisher MM. Mechanisms in IgE-dependent anaphylaxis to anaesthetic drugs. Ann Fr Anesth Reanim 1993; 12: 131-40.
94. Didier A, Cador D, Bongrand P, et al. Role of the quaternary ammonium ion determinants in allergy to muscle relaxants. J Allergy Clin Immunol 1987; 79: 578-84.
95. Vervloet D, Arnaud A, Senft M, Didier A, Bongrand P, Charpin J. Anaphylactic reactions to suxamethonium. Prevention of mediator release by choline. J Allergy Clin Immunol 1985; 76: 222-5.
96. Baldo B, Fisher M, Pham N. On the origin and specificity of antibodies to neuromuscular blocking (muscle relaxant) drugs. An immunochemical perspective. Clin Exp Allergy 2009; 39: 325-44.
97. Florvaag E. Anaphylactic reactions during general anaesthesia. New Horiz 2005; 2: 1-6.
98. Florvaag E, Johansson SGO. The pholcodine story. Immunol Allergy Clin North Am 2009; 29: 419-27.
99. Florvaag E, Johansson SGO, Öman H, Harboe T, Nopp A. Pholcodine stimulates a dramatic increase of IgE in IgE-sensitized individuals. A pilot study. Allergy 2006; 61: 49-55.
100. Florvaag E, Johansson SGO, Öman H, et al. Prevalence of IgE antibodies to morphine. Relation to the high and low incidences of NMBA anaphylaxis in Norway and Sweden, respectively. Acta Anaesthesiol Scand 2005; 49: 437-44.
101. Johansson SG, Florvaag E, Oman H, et al. National pholcodine consumption and prevalence of IgE-sensitization: a multicentre study. Allergy 2010; 65: 498-502.
102. Flacke JW, Flacke WE, Bloor BC, Van Etton AP, Kripke BJ. Histamine release by four narcotics: a double-blind study in humans. Anaesth Analg 1987; 68: 723-30.
103. Harle DG, Baldo BA, Coroneos NJ, Fisher MM. Anaphylaxis following administration of papaveretum. Case report: implication of IgE antibodies that react with morphine and codeine, and identification of an allergenic determinant. Anesthesiology 1989; 71: 489-94.
104. Mayer JP, Zhang F, DiMarchi RD. Insulin structure and function. Biopolymers 2007; 88: 687-713.
105. Scherntaner G. Immunogenicity and allergenic potential of animal and human insulins. Diab Care 1993; 16: 155-65.
106. Patterson R, Roberts M, Grammer LC. Insulin allergy: re-evaluation after two decades. Ann Allergy 1990; 64: 459-62.
107. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diab Care 1990; 13: 923-54.
108. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS. Immunological responses to exogenous insulin. Endocr Rev 2007; 28: 625-52.
109. Kumar D. Immunoreactivity of insulin antibodies in insulin-treated diabetics: significance of the beta-chain carboxy-terminal amino acid (B-30) of insulin. Diabeted 1979; 28: 994-1000.
110. Yokoyama H, Fukumoto S, Koyama H, Emoto M, Kitagawa Y, Nishizawa Y. Insulin allergy: desensitization with crystalline zinc-insulin and steroid tapering. Diabetes Res Clin Pract 2003; 61: 161-6.
111. Luyasu S, Hougardy N, Hasdenteufel F, et al. Anaphylactic shock to human insulin: follow-up of a desensitization protocol by basophil activation tests. Rev Med Interne 2011; 32: 39-42.
112. Sola-Gazagnes A, Pecquet C, M'Bemba J, Larger E, Slama G. Type I and type IV allergy to the insulin analogue detemir. Lancet 2007; 369: 637-8.
113. Morisset M, Moneret-Vautrin DA, Loppinet V, Grandidier S. Cross-allergy to ranitidine and nizatidine. Allergy 2000; 55: 682-3.
114. Herborn CU, Honold E, Wolf M, Kemper J, Kinner S, Adam G, Barkhausen J. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol 2007; 42: 58-62.
115. Li A, Wong CS, Wong MK, Lee CM, Au Yeung MC. Acute adverse reactions to magnetic resonance contrast media - gadolinium chelates. Br J Radiol 2006; 79: 368-71.
116. Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol 2008; 66: 160-7.
117. Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 2008; 66: 175-9.
118. Hasdenteufel F, Luyasu S, Renaudin JM, et al. Anaphylactic shock after first exposure to gadoterate meglumine: two case reports documented by positive allergy assessment. J Allergy Clin Immunol 2008; 121: 527-8. Reply. J Allergy Clin Immunol 2008; 122: 216-7.